Site Visit

RNS Number : 7506F
Advanced Medical Solutions Grp PLC
19 January 2010

For immediate release

 19 January 2010

Advanced Medical Solutions Group plc 

(“AMS” or “the Company”)

Analyst and Investor Site Visit

WinsfordUKAdvanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, is today hosting a site visit for analysts and institutional investors at its new world-class medical device facility in Winsford, Cheshire.

AMS is consolidating two existing premises in Winsford into the new leasehold facility, where the Company will manufacture products for its global strategic partners and for its direct sales of the ActivHeal® range. The facility, which provides capacity for the Company’s planned future growth, will also accommodate AMS’s managerial and administrative offices, R&D laboratories and warehousing.  

No new material information will be disclosed.

For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

  Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Gary Clarence / Tim Pratelli / Daniel Adams

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its in-house technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

This information is provided by RNS
The company news service from the London Stock Exchange